SUSTAINED EFFICACY OF BIMEKIZUMAB TREATMENT ASSESSED USING COMPOSITE DISEASE ACTIVITY MEASURES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROMTHE PHASE 3 BE COMPLETE STUDY AND ITS OPEN LABEL EXTENSION UP TO 1 YEAR

被引：0
|
作者：
Coates, L. [1 ,2 ]
Landewe, R. B. M. [3 ]
Mcinnes, I. [4 ]
Ritchlin, C. T. [5 ]
Gottlieb, A. B. [6 ]
Orbai, A. M. [7 ]
Warren, R. B. [8 ]
Ink, B. [9 ]
Bajracharya, R.
Coarse, J. [10 ]
Merola, J. F. [11 ]
机构：
[1] Univ Oxford, Oxford Univ Hosp NHS Trust, Nuffield Dept Orthopaed, Rheumatol & Musculoskeletal Dis, Oxford, England
[2] Oxford Biomed Res Ctr, Oxford, England
[3] Amsterdam & Zuyderland MC, Amsterdam Rheumatol Clin Immunol Ctr, Heerlen, Netherlands
[4] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow, Scotland
[5] Univ Rochester, Allergy Immunol Rheumatol Div, Med Sch, Rochester, NY USA
[6] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA
[7] Johns Hopkins Univ, Div Rheumatol, Sch Med, Baltimore, MD USA
[8] Univ Manchester, Salford Royal NHS Fdn Trust, Dermatol Ctr, Manchester NIHR Biomed Res Ctr, Manchester, England
[9] UCB Pharma, Slough, Berks, England
[10] UCB Pharma, Morrisville, NY USA
[11] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Clinical trials; Psoriatic arthritis;
D O I：
10.1136/annrheumdis-2023-eular.1671
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB1099
引用
收藏
页码：1775 / 1776
页数：2
相关论文
共 32 条
  • [1] SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN-LABEL EXTENSION UP TO 1 YEAR
    Coates, L.
    Landewe, R. B. M.
    Mcinnes, I.
    Mease, P. J.
    Ritchlin, C. T.
    Tanaka, Y.
    Asahina, A.
    Behrens, F.
    Gladman, D. D.
    Gossec, L.
    Gottlieb, A. B.
    Warren, R. B.
    Ink, B.
    Bajracharya, R.
    Coarse, J.
    Merola, J. F.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 346 - 347
  • [2] Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: Results from the phase 3 BE COMPLETE study and its open-label extension up to 1 year
    Coates, L.
    Landewe, R. B. M.
    McInnes, I.
    Mease, P. J.
    Ritchlin, C. T.
    Tanaka, Y.
    Asahina, A.
    Behrens, F.
    Gladman, D. D.
    Gossec, L.
    Gottlieb, A. B.
    Warren, R. B.
    Ink, B.
    Bajracharya, R.
    Coarse, J.
    Giger, S.
    Merola, J. F.
    SWISS MEDICAL WEEKLY, 2023, 153 : 24S - 25S
  • [3] Bimekizumab efficacy and safety in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: Results from BE COMPLETE and its open-label extension to 1 year
    Coates, L.
    Landewe, R.
    Mclnnes, I.
    Mease, P.
    Ritchlin, C.
    Tanaka, Y.
    Asahina, A.
    Behrene, F.
    Gladman, D.
    Gossecic, L.
    Gottlieb, A.
    Warren, R.
    Ink, B.
    Bajracharya, R.
    Coarse, J.
    Neregard, P.
    Merola, J.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2023, 52 : 81 - 83
  • [4] Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
    Coates, Laura C.
    Landewe, Robert
    Mcinnes, Iain B.
    Mease, Philip J.
    Ritchlin, Christopher T.
    Tanaka, Yoshiya
    Asahina, Akihiko
    Behrens, Frank
    Gladman, Dafna D.
    Gossec, Laure
    Orbai, Ana-Maria
    Gottlieb, Alice B.
    Warren, Richard B.
    Ink, Barbara
    Bajracharya, Rajan
    Shende, Vishvesh
    Coarse, Jason
    Merola, Joseph F.
    RMD OPEN, 2024, 10 (01):
  • [5] Bimekizumab Treatment in Patients with Active PsA and Prior Inadequate Response to TNF Inhibitors: Sustained Efficacy and Safety Results from a Phase 3 Study and Its Open-Label Extension up to 1 Year
    Coates, Laura
    Landewe, Robert B. M.
    McInnes, Iain
    Mease, Philip J.
    Ritchlin, Christopher T.
    Tanaka, Yoshiya
    Asahina, Akihiko
    Behrens, Frank
    Gladman, Dafna
    Gossec, Laure
    Gottlieb, Alice B.
    Warren, Richard B.
    Ink, Barbara
    Bajracharya, Rajan
    Coarse, Jason
    Merola, Joseph
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4401 - 4404
  • [6] BIMEKIZUMAB MAINTAINED EFFICACY RESPONSES THROUGH 52 WEEKS IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO TUMOUR NECROSIS FACTOR INHIBITORS WHO WERE RESPONDERS AT WEEK 16: RESULTS FROM A PHASE 3, RANDOMISED STUDY
    Tillett, William R.
    Merola, Joseph F.
    Tanaka, Yoshiya
    Favalli, Ennio G.
    McGonagle, Dennis
    Thaci, Diamant
    Walsh, Jessica A.
    Ink, Barbara
    Bajracharya, Rajan
    Coarse, Jason
    Ritchlin, Christopher T.
    RHEUMATOLOGY, 2024, 63
  • [7] Bimekizumab maintained efficacy responses through 52 weeks in patients with psoriatic arthritis and inadequate response or intolerance to tumour necrosis factor inhibitors who were responders at week 16: results from a phase 3, randomised study
    Tillett, William R.
    Merola, Joseph F.
    Tanaka, Yoshiya
    Favalli, Ennio G.
    Mcgonagle, Dennis
    Thaci, Diamant
    Walsh, Jessica A.
    Ink, Barbara
    Bajracharya, Rajan
    Coarse, Jason
    Ritchlin, Christopher T.
    RHEUMATOLOGY, 2024, 63
  • [8] Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
    Merola, Joseph F.
    Landewe, Robert
    McInnes, Iain B.
    Mease, Philip J.
    Ritchlin, Christopher T.
    Tanaka, Yoshiya
    Asahina, Akihiko
    Behrens, Frank
    Gladman, Dafna D.
    Gossec, Laure
    Gottlieb, Alice B.
    Thaci, Diamant
    Warren, Richard B.
    Ink, Barbara
    Assudani, Deepak
    Bajracharya, Rajan
    Shende, Vishvesh
    Coarse, Jason
    Coates, Laura C.
    LANCET, 2023, 401 (10370): : 38 - 48
  • [9] BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: 16-WEEK EFFICACY & SAFETY FROM BE COMPLETE, A PHASE 3, MULTICENTRE, RANDOMISED PLACEBO-CONTROLLED STUDY
    Merola, J. F.
    McInnes, I.
    Ritchlin, C. T.
    Mease, P. J.
    Landewe, R. B. M.
    Asahina, A.
    Tanaka, Y.
    Warren, R. B.
    Gossec, L.
    Gladman, D. D.
    Behrens, F.
    Ink, B.
    Assudani, D.
    Bajracharya, R.
    Coarse, J.
    Coates, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 167 - 169
  • [10] Bimekizumab Safety and Efficacy in Patients with Psoriatic Arthritis: 3-Year Results from a Phase 2b Open-Label Extension Study
    Coates, L. C.
    Warren, R. B.
    Ritchlin, C. T.
    Gossec, L.
    Merola, J. F.
    Assudani, D.
    Coarse, J.
    Eells, J.
    Ink, B.
    McInnes, I. B.
    SWISS MEDICAL WEEKLY, 2021, 151 : S20 - S20
1234